Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
April 14, 2015
Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing
Barbara Bartolini, Raffaella Lionetti, Emanuela Giombini, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 17, 2012
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir
Ellen G J Hulskotte, Hwa-Ping Feng, Fengjuan Xuan, et al.
Antiviral Therapy
|
January 23, 2014
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b
Fiona McPhee, Dennis Hernandez, Nannan Zhou, et al.
Journal of Clinical and Translational Science
|
October 31, 2024
Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future
Stacey J Adam, Timothy G Buchman, Judith S Currier, et al.
Hepatology (Baltimore, Md.)
|
October 13, 2010
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
Joep de Bruijne, Jilling F Bergmann, Henk W Reesink, et al.
World Journal of Gastroenterology
|
March 30, 2016
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1
Ira Jacobson, Stefan Zeuzem, Robert Flisiak, et al.
The Lancet. Infectious Diseases
|
June 21, 2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
Stanislas Pol, Reem H Ghalib, Vinod K Rustgi, et al.
JAMA
|
May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
Andrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Journal of Hepatology
|
October 11, 2015
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Stefan Zeuzem, Christophe Hézode, Jean-Pierre Bronowicki, et al.
Hepatology (Baltimore, Md.)
|
January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
David R Nelson, James N Cooper, Jacob P Lalezari, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
April 14, 2015
Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing
Barbara Bartolini, Raffaella Lionetti, Emanuela Giombini, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 17, 2012
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir
Ellen G J Hulskotte, Hwa-Ping Feng, Fengjuan Xuan, et al.
Antiviral Therapy
|
January 23, 2014
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b
Fiona McPhee, Dennis Hernandez, Nannan Zhou, et al.
Journal of Clinical and Translational Science
|
October 31, 2024
Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future
Stacey J Adam, Timothy G Buchman, Judith S Currier, et al.
Hepatology (Baltimore, Md.)
|
October 13, 2010
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
Joep de Bruijne, Jilling F Bergmann, Henk W Reesink, et al.
World Journal of Gastroenterology
|
March 30, 2016
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1
Ira Jacobson, Stefan Zeuzem, Robert Flisiak, et al.
The Lancet. Infectious Diseases
|
June 21, 2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
Stanislas Pol, Reem H Ghalib, Vinod K Rustgi, et al.
JAMA
|
May 6, 2015
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
Andrew J Muir, Fred Poordad, Jacob Lalezari, et al.
Journal of Hepatology
|
October 11, 2015
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Stefan Zeuzem, Christophe Hézode, Jean-Pierre Bronowicki, et al.
Hepatology (Baltimore, Md.)
|
January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
David R Nelson, James N Cooper, Jacob P Lalezari, et al.
Page
of 3